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Abstract Stimulation of p21-activated kinase-1 (Pak1) and es-
tradiol-estrogen receptor-K in mammary cancer cells promotes
cell survival. We sought to determine whether estrogen stimu-
lates the Pak1 pathway. We found that estrogen rapidly acti-
vated Pak1 kinase activity in a phosphatidylinositol 3-kinase-
insensitive manner. Furthermore, estrogen induced phosphory-
lation and perinuclear localization of the cell survival forkhead
transcription factor FKHR in the cytoplasm in a Pak1-depen-
dent manner. In addition, Pak1 directly interacted with FKHR
and phosphorylated it. The noticed phosphorylation-dependent
exclusion of FKHR from the nucleus impaired the ability of
FKHR to activate its target Fas ligand promoter containing
the FKHR binding motif (FRE) in cells treated with estrogen
or expressing catalytically active Pak1. In contrast, expression
of the dominant-negative auto-inhibitory domain of Pak1 (Pak
amino acids 83^149) promoted the ability of FKHR to activate
transcription from FRE. Together, these results identify a novel
signaling pathway linking estrogen action to Pak1 signaling,
and Pak1 to FKHR, suggesting that Pak1 is an important
mediator of estrogen’s cell survival functions.
1 2002 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
P21-activated kinase (Pak1), a well characterized serine/
threonine kinase [1,2] and e¡ector protein of phosphatidylino-
sitol 3-kinase (PI-3K) [1], mediates the cellular e¡ect of poly-
peptide growth factor on cell motility [3], invasiveness [4],
anchorage-independent growth [5,6], and cell survival of hu-
man breast cancer cells. Pak1 is an e¡ector of small GTPase
cdc42 and Rac1 [7] and binding of activated GTPase to Pak1
regulates the phosphorylation and kinase activity of Pak1.
Activation of Pak1 by diverse signals leads to autophosphor-
ylation at several sites, including threonine 423 (T423) within
the activation loop of kinase domain [2,5]. Pak1 also modu-
lates the activation status of signaling pathways such as mi-
togen-activated protein kinase (MAPK) and p38MAPK [8].
The development of human breast cancer is promoted by
estrogen (E2) stimulation of mammary epithelial cell growth
[9]. The biological e¡ects of E2 are mediated by its binding to
the structurally and functionally distinct estrogen receptors
(ER) K and L. ERK is the major ER in the mammary epithe-
lium [10]. Upon the binding of E2 to ERK, ligand-activated
ERK translocates to the nucleus, and stimulates gene tran-
scription, thus promoting the growth of breast cancer cells
[11]. In addition to the transcription e¡ect of E2, it is increas-
ingly accepted that ligand-activated ERK regulates a series of
non-genomic events in the cytoplasm [12] including the acti-
vation of PI-3K [13]. Because both Pak1 and ERK have been
implicated in the progression of breast cancer and because
Pak1 is downstream of PI-3K, we sought to determine
whether Pak1 has a function in ER signaling and whether
E2 utilizes Pak1 to facilitate cell survival.
The consistent involvement of members of the cell survival
forkhead transcription factor (FKHR) in chromosomal trans-
locations found in cancer suggests that FKHR plays an im-
portant role in regulation of cellular proliferation and di¡er-
entiation [14]. Several recent studies have shown that FKHR
promotes the expression of pro-apoptotic genes such as Fas
ligand (FasL) and FKHR phosphorylation triggers its nuclear
exclusion and inhibition of pro-apoptotic function [14^16].
The cell survival signaling kinase AKT has been shown to
phosphorylate FKHR and support cell survival in mammalian
cells [17^19]. Since Pak1 is downstream of AKT and since
both Pak1 and FKHR are components of the cell survival
pathway, here we investigated whether Pak1 could modulate
the functions of FKHR in relation to E2 signaling in breast
cancer cells.
2. Materials and methods
2.1. Cell cultures, transfection, cell extracts and reagents
Human breast cancer cells MCF-7 were cultured in phenol red-free
medium supplemented with 5% charcoal stripped serum (DCC se-
rum). For E2 treatment cells were E2-deprived for 48 h before treat-
ment. For preparation of cell extracts, cells were washed three times
with phosphate-bu¡ered saline and lysed in bu¡er (50 mM Tris^HCl,
pH 7.5; 120 mM NaCl; 0.5% NP-40; 100 mM NaF; 2 mM NaVO5 ;
1 mM phenylmethylsulfonyl £uoride; 10 Wg/ml leupeptin; 10 Wg/ml
aprotinin) for 30 min on ice. The lysates were centrifuged in an Ep-
pendorf centrifuge at 4‡C for 15 min. Cell lysates containing equal
amounts of protein were resolved on 10% SDS^polyacrylamide gel,
transferred to nitrocellulose, and probed with appropriate antibodies.
Antibodies against phospho-AKT-473, total AKT, phospho-FKHR-
Ser-256 and total FKHR were purchased from Cell signaling Tech-
nology, USA. Anti-Pak1 antibody was from Neomarker, USA. Trans-
fection was performed using the Fugene-6 kit (Roche Biochemical) as
per the manufacturer’s instruction.
2.2. Promoter-reporter assay
FKHR-Luc (FRE-Luc) plasmid and wild-type (WT) FKHR were
obtained from Michael Greenberg (Harvard Medical School, Boston,
MA, USA) [20]. For promoter assay cells were transiently cotrans-
fected with a reporter construct and L-galactosidase. Cells were har-
vested with passive lysis bu¡er (Promega) and measured for luciferase
activity.
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2.3. In vitro transcription and translation
In vitro transcription and translation of a desired protein were
performed using the Transcription-Translation system (Promega) as
described [21]. One Wg of test plasmid was in vitro translated in the
presence of 35S in a reaction volume of 50 Wl. The reaction was diluted
to 1 ml with NP-40 lysis bu¡er and an aliquot (250 Wl) was used for
each glutathione S-transferase (GST) pull-down assay. Translation
was veri¢ed by running 20 Wl of reaction on SDS^PAGE and auto-
radiography.
2.4. GST pull-down and in vitro kinase assays
GST pull-down assays were performed by incubating equal
amounts of GST, GST-AF2, GST-WT Pak1, GST-WT FKHR, pro-
teins immobilized to glutathione beads Sepharose (Amersham) with in
vitro translated 35S-labeled protein [21]. The mixture was incubated
for 2 h at 4‡C, washed with NP-40 lysis bu¡er, bound proteins were
eluted with 2USDS bu¡er, separated on SDS^PAGE and developed
by £uorography. In vitro kinase assay was performed using immuno-
precipitation with anti-Pak1 antibody for 4 h at 4‡C followed by ki-
nase reaction in kinase bu¡er (20 mM HEPES pH 7.2; 10 mM
MgCl2 ; 10 mM MnCl2 ; 1 mM dithiothreitol) containing 10 WCi of
[Q-32P]ATP and 25 WM of cold ATP. Reaction was performed in a
volume of 40 Wl for 30 min at 30‡C
2.5. Immuno£uorescence and confocal imaging
MCF-7 cells were plated on glass coverslips in six-well culture
plates. When the cells were approximately 50% con£uent, they were
serum-starved for 36 h. Alternatively, 30% con£uent MCF-7 cells
were maintained in 5% DCC serum for 48 h, then were treated with
L-estradiol (1039 M) for 30 min with or without pretreatment with the
anti-estrogen ICI 182780 (1038 M) for 1 h. Cells were rinsed in phos-
phate-bu¡ered saline, ¢xed in cold 100% methanol for 6 min, then
blocked and incubated with primary antibodies against FKHR and
myc-tagged followed by £uorochrome-tagged secondary antibodies.
Confocal analysis were performed using an LSM510 Zeiss microscope
[3^5].
3. Results and discussion
Since E2 has been shown to activate PI-3K and Akt as well
as promote cell survival, we wondered whether E2 could also
activate Pak1, a downstream target of PI-3K. To explore this
possibility, ER-positive MCF-7 cells were treated with E2 in
the presence of Ly 294002 (a speci¢c inhibitor of PI-3K) or
ICI 182780 (a pure anti-estrogen). E2 stimulation of cells was
accompanied by a rapid stimulation of Pak1 activity that was
blocked by ICI 182780 but not by Ly 294002 (Fig. 1A). How-
ever, ICI 182780 blocked E2-mediated Akt stimulation. E2
also activated Pak1 activity in murine mammary glands cul-
tured in vitro (Fig. 1B). These observations suggested that E2
activates Pak1 activity in a PI-3K-independent manner.
To understand the signi¢cance of E2-induced activation of
Pak1, a cytoplasmic kinase, we hypothesized that E2 utilizes
Pak1 signaling to promote cell survival by phosphorylating
FKHR, which was previously shown to be phosphorylated
via the PI-3K/Akt pathway [17^19]. Stimulation by E2 in
MCF-7 cells was accompanied by increased phosphorylation
of FKHR on Ser-256, and this e¡ect was inhibited by ICI
182780 (Fig. 2A). Using confocal microscopy, we further
demonstrated that E2 induces perinuclear cytoplasmic local-
ization (green) of the phosphorylated FKHR as compared to
non-stimulated or ICI 182780-pretreated cells in which phos-
pho-FKHR is within the nucleus (Fig. 2B). To demonstrate
the impact of Pak1 signaling on FKHR subcellular distribu-
tion, we showed that transient expression of Myc-tagged (red)
WT Pak1 but not dominant-negative K299R Pak1 [4] enhan-
ces the level of phosphorylated FKHR (green) in the cyto-
plasm of MCF-7 cells (Fig. 2C). Interestingly, phosphorylated
FKHR was also co-localized with WT Pak1 as shown by the
development of yellow pixels due to overlapping of red and
green pixels (Fig. 2C). Transfection of dominant-negative
Pak1 (K299RLL, red) also inhibited the ability of E2 to re-
distribute phosphorylated FKHR (green) from the nucleus to
the cytoplasm (Fig. 2C).
To determine whether the observed association between
Myc-Pak1 and FKHR was direct or mediated via other pro-
teins, we examined the ability of in vitro translated FKHR
protein to bind with GST WT Pak1. As shown in Fig. 3A,
Fig. 1. E2 stimulation of the Pak1 activity. A: MCF-7 breast cancer
cells were grown in phenol red-free Dulbecco’s modi¢ed Eagle’s me-
dium^F12 (1:1) supplemented with 5% charcoal-stripped fetal calf
serum for 48 h. MCF-7 cells were treated with 1039 M E2 in the
presence or absence of ICI 182780 (1038 M) or LY294002 (20 WM)
for 10 min, and Pak1 kinase activity was assayed using myelin basic
protein (MBP) as a substrate. B: E2 regulation of Pak1 kinase ac-
tivity in explanted mouse mammary gland tissues of mice using
MBP as a substrate (n=3). C: MCF-7 cells treated with or without
Ly 294002 (20 WM, lanes 4 and 5) were stimulated with E2 (1039 M
for 30 min (lanes 3 and 4) or 10 min (lane 2)). Cell lysates were im-
munoblotted with the indicated antibodies.
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Fig. 2. E2 regulation of the FKHR pathway. A: E2 induced FKHR phosphorylation. MCF-7 cells were treated of 1039 M E2 with or without
ICI 182780 (1038 M) or LY294002 (20 WM) for the indicated times. Cell lysates were prepared and were resolved on a 10% SDS^polyacryl-
amide gel, transferred to nitrocellulose, and probed with an antibody against FKHR Ser-256. The blot was reprobed with a vinculin antibody.
B: E2 regulation of FKHR subcellular distribution. MCF-7 cells were grown in phenol red-free medium with 5% charcoal-stripped fetal calf se-
rum for 48 h. Cells were treated with 1039 M E2 in the presence or absence of ICI 182780 (1038 M) for 10 min. Cells grown on glass cover-
slips were ¢xed (without permeabilization) at 320‡C for 6 min. Confocal analysis was used to determine the FKHR localization using anti-
phosphorylated Ser-256 FKHR antibody. Each image represents Z sections at the same cellular level and magni¢cation. Confocal analysis was
performed using a Zeiss laser scanning confocal microscope and the established methods [22], involving processing of the same section for each
detector (the two excitations corresponding to 546 and 488 nm) and comparing pixel by pixel. Co-localization of two proteins is demonstrated
by the development of yellow color due to red and green overlapped pixels. C: MCF-7 cells were transfected with Myc-tagged wild-type (WT)
or dominant-negative K299R (DN) Pak1, and cells were treated with or without 1039 M E2 (30 min), and analyzed by indirect immuno£uores-
cence and confocal microscopy using antibodies directed against Myc (for Pak1, red) and phosphorylated Ser-256 FKHR (green). For controls,
cells were treated only with the secondary antibodies (n=3).
FEBS 26890 16-1-03
A. Mazumdar, R. Kumar/FEBS Letters 535 (2003) 6^108
FKHR interacted with GST-Pak1, but not with GST alone in
GST pull-down assays. However, GST pull-down assays using
cell extracts from untreated or E2 (1039 M for 30 min)treated
MCF-7 cells demonstrated that cellular FKHR interacted
with GST-WT Pak1 only in an E2-dependent manner (Fig.
3B), suggesting that E2-mediated modi¢cation of FKHR may
be important for its binding to Pak1. To understand ER reg-
ulation of FKHR, GST pull-down assays were performed.
FKHR interacted strongly with GST-AF2 but not with
GST alone (Fig. 3C). Next we determined whether FKHR
is a substrate of Pak1 by performing in vitro kinase assays
with puri¢ed Pak1 enzyme and GST-FKHR as a substrate.
Pak1 e⁄ciently phosphorylated GST-FKHR (Fig. 3D).
Phosphorylation of FKHR is known to promote both its
exclusion from the nucleus and its cell survival function, thus
impairing the ability of FKHR to transactivate its target
genes [18^20]. Next, we examined the e¡ects of E2 and
Pak1 expression on the ability of FKHR to activate a FasL
promoter containing the FKHR binding motif (FRE) [20]. As
shown in Fig. 4A, pretreatment with E2 as well as expression
of catalytically active Pak1 (T423E) prevented the stimulation
of FasL-Luc activity by FKHR. In contrast, expression of the
dominant-negative auto-inhibitory domain of Pak1 (Pak ami-
no acids 89^143) [22] promoted the ability of FKHR to acti-
vate transcription from the FRE-containing reporter system
(Fig. 4A), suggesting that Pak1 signaling might impair pro-
apoptotic functions of FKHR.
Our ¢ndings suggest that E2 activates Pak1 signaling in an
ER-dependent manner without involving PI-3K. Findings
that FKHR can interacts directly with Pak1 and can be phos-
phorylated by both E2 and Pak1 have a signi¢cant impact on
FKHR translocation and thereby on cell survival. These re-
sults suggest a model (Fig. 4B) wherein Pak1 regulation of
FKHR phosphorylation may support cell survival by impair-
ing its pro-apoptotic nuclear function due to exclusion of
phosphorylated FKHR from the nucleus and/or by preventing
the translocation of FKHR from the cytoplasm to the nu-
cleus. In summary, we provide new evidence that Pak1 is a
signaling component of E2 action, Pak1 in£uences the cell
survival FKHR, and Pak1 acts as an important mediator of
the cell survival function of E2.
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